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FLOW CYTOMETRY MONITORING OF AMPLIFIED OLIGOCLONAL T-
CELL POPULATIONS IN PERIPHERAL BLOOD (PBL) OF GRAFT VERSUS
HOST DISEASE (GVHD) PATIENTS SUBMITTED TO EXTRACORPOREAL
PHOTOTHERAPY (ECP): IMPACT ON THE OUTCOME EVALUATION
Tassi, C.; Tazzari, P.L.; Ricci, F.; Conte, R. Medical Transfusion
Center-Sant’Orsola Hospital, Bologna, Italy.
A positive correlation has been described between circulating
oligoclonal T-cell subsets and clinical response to ECP in acute
and chronic GVHD patients. A quantitative VBeta domains ﬂow
cytometry analysis can be performed by means of the IOTest Beta
Mark (Beckmann-Coulter), a kit constituted of labelled monoclo-
nal antibodies directed against the more frequently detectable
VBeta domains. A clonal T-cell expansion can be suspected when
the VBeta subset is 20%. We analysed the VBeta repertoire in 5
cGVHD and 1 aGVHD patients, all submitted to ECP according
to the designed protocols. The mean follow-up was 6 months
(min2, max12), with a mean of 23 (10–40) ECP courses per-
formed per patient. Before and after every ECP cycle, PBL samples
were submitted to differential absolute white blood cells (WBC)
count and cytometry analysis for: i) phenotype, main NK, T and B
lymphocyte antigens; ii) the VBeta study previously described. In
agreement with other studies performed by means of molecular
methods, our cytometry analysis disclosed some recurrent, oligo-
clonal VB/CD8 subsets, frequently showed in patients suffering
for GVHD. In particular, VB12 in 2/6 patients, VB14 in 4/6, VB16
in 2/6, VB20 in 4/6, VB5.2 in 2/6, VB 21.3 in2/6. Moreover, other
VB subsets, sometimes correlated with responses directed against
the lymphoid or myeloid cells (namely VB5.3, VB5.2, VB5.1,
VB13.2 and VB3), were detectable before the ECP in one MM,
one ALL and in one HL patient. The CD4:CD8 ratio got back to
normal in 4/6 patients after a mean of 4 months (2–6). Skin lesions
completely cleared up in 2/6 cases, while a partial response was
observed in 2/6, a stable-steroids dependent skin disease in 1/6 and
a disease progression in 1/6. No liver modiﬁcations were observed
in 1/1 patient; oral mucosal lesions signiﬁcantly improved in 3/3.
In partial or complete responses, the VB subsets previously de-
tected disappeared after few ECP courses and remained below
normal values in the follow-up, showing moderate ﬂuctuations in
partial responding patients. By contrast, in the progressive and in
the stable cGVHDs, the initially reduced VB14CD8 dramatically
increased during ECP treatment. In conclusion, ﬂow cytometry
analysis on GVHD PBL samples enabled us to demonstrate the
presence of oligoclonal VB subsets, whose kinetic trend seems to
anticipate the clinical response to immunosuppressive therapy/
ECP and could be used as early marker of response to ECP.
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PRAME-SPECIFIC CD8 T CELLS ARE SPONTANEOUSLY PRESENT IN A
LARGE PROPORTION OF HEALTHY DONORS AND LEUKEMIC HLA-
A0201 PATIENTS
Rezvani, K.1; Tawab, A.1; Kilical, Y.1; Sconocchia, G.1; Li, J.1; Hensel,
N.1; Kurlander, R.2; Barrett, J.1 1. Stem Cell Allotransplantation
Section, Hematology Branch, National Institutes of Health, Bethesda,
MD; 2. Department of Laboratory Medicine, National Institutes of
Health, Bethesda, MD.
The tumor antigen PRAME is expressed in up to 50% of patients
with AML. Four HLA-A*0201-restricted PRAME T cell epitopes
have been identiﬁed: P100-108 (P100), P142-151 (P142), P300-
309 (P300) and P425-433 (P425). To detect very low frequencies
of PRAME-speciﬁc CD8 T cells, we used quantitative real-time
reverse transcription polymerase chain reaction (qPCR) to measure
interferon- mRNA (IFN-) production by PRAME peptide
pulsed CD8 T cells from 11 HLA-A*0201 healthy donors and
10 HLA-A*0201 patients with AML, one of whom had received
an allogeneic stem cell transplant (SCT). Peptides were loaded
onto an MHC class I-defective cell line (C1R-A2) at concentra-
tions of 0.1, 1 and 10 mM. CMV pp65 and gp100 peptides served
as positive and negative controls respectively. C1R-A2 cells were
cocultured for 3 h with 106 CD8 T cells, RNA was extracted and
qPCR was performed for IFN- mRNA and normalized to copies
of CD8 mRNA from the same sample. A positive response was
deﬁned as 100 IFN- mRNA copies/104 CD8 copies and a
stimulation index (pulsed/unpulsed) of 2. The assay detected
frequencies as low as 1/100,000 peptide-speciﬁc CD8 T cells.
Eight of the eleven healthy donors and 7/10 AML patients showed
peptide-speciﬁc IFN production. Four of eight healthy donors
and 5/7 AML patients recognized 2–3 PRAME epitopes. The
mean response against PRAME epitopes was greater in leukemic
patients compared with healthy donors (3597–9371 versus 172–
1288 IFN-mRNA copies). PRAME peptide P300 responses were
also detected with an optimized ELISPOT assay in 2/4 AML
patients and 5/8 normal donors. Of 8 qPCR positive donors, 6
were positive by ELISPOT conﬁrming IFN- mRNA transcrip-
tion was associated with IFN secretion. The most immunogenic
epitope in donors and patients was P300 with 6 concordant qPCR
and ELISPOT assays. In 2/5 samples tested (1 donor and 1 pa-
tient), peptide-speciﬁc ELISPOT responses expanded 2–10 fold
after 7 days culture. An AML patient undergoing transplant was
also studied. The donor had CD8 reactivity to P142, P300 and
P425. The patient had no PRAME response prior to SCT but after
SCT responded to P142 and P425 and P100, suggesting the
transfer and expansion of PRAME-speciﬁc CD8 T cells from
donor to recipient. These results provide the ﬁrst evidence for
spontaneous T-cell reactivity against PRAME in healthy donors
and AML patients. They support the potential of PRAME for
immunotherapy of leukemia.
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OPTIMIZATION OF CULTURE METHODS FOR THE EXPANSION OF
CD4CD25 REGULATORY T CELLS FOR POTENTIAL CLINICAL USE
Keever-Taylor, C.A.; Browning, M.B.; Johnson, B.D.; Behn, B.; Truitt,
R.L. Medical College of Wisconsin, Milwaukee, WI.
CD4CD25 T cells mediate potent suppression of T cell re-
sponses and may be essential for control of autoimmune responses.
We have shown that donor-derived T regulatory cells (Treg)
prevent graft vs host disease associated with donor lymphocyte
infusion in murine models. In anticipation of clinical use we per-
formed a series of experiments to optimize the isolation and ex-
pansion of suppressive Treg cells. To this end buffy coat mono-
nuclear cells obtained from 19 blood donors were positively
selected for CD25 cells using either auto-MACS or mini-MACS
devices. Freshly isolated, CD25-enriched cells were 96 	 2%
CD25, 84 	 5% CD4CD25, and 5 	 4% CD8. Selected
cells were expanded in Ex Vivo-15 medium-5% human serum
using CD3/CD28 antibody-coated beads and IL-2 (100 IU/
mL). Culture condition variations included: expansion in ﬂasks vs
plates, bead:cell ratio of 4:1 vs 3:1, IL-2 added on d 3 vs d 1, use of
a 1:1 ratio of irradiated CD4 feeders vs no feeders and main-
taining cell density at 106/mL vs 0.5  106/mL. Cells expanded
equally well in plates or ﬂasks and cells expanded moderately faster
using a bead:cell ratio of 4:1 with IL-2 added on d 3 of culture. The
most dramatic improvement occurred when cultures were main-
tained at 0.5  106/mL (76 fold at d 12 & 210 fold at d 14) instead
of 106/mL (5 fold at d 12 & 10 fold at d 14). Suppressive activity
of expanded lines was tested using mixed lymphocyte cultures
(MLC) between autologous responder CD4CD25 cells and
allogeneic dendritic cells. Optimal suppression occurred between d
7 and d 12 of expansion, but good suppression was maintained in
most cultures at d 14. MLC suppression remained relatively stable
ranging from 81 	 16% to 75 	 17% at 1:1 to 1:16 Treg:
responders and declined to 17 	 14% at 1:128. Freezing had little
effect on Treg suppressor activity. Treg at 1:1 completely inhibited
the generation of alloreactive cytotoxic T lymphocytes (CTL) but
only partially (50%) inhibited the generation of EBV-reactive
CTL suggesting that Treg may be more sparing of viral speciﬁc T
cell responses. There was no effect on NK mediated cytotoxicity.
From these data we project a starting apheresis product would yield
on average 2.0  108 Treg/kg for infusion by d 12 and 6  108
Treg/kg by d 14 for a 75 kg adult. These data show that Treg cells
with potent suppressor activity can be expanded from CD25-
enriched cells using CD3/CD28 coated beads in as few as 10–12
days in numbers sufﬁcient for clinical trials.
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